TENX - יחס חוב להיוון בספרים Tenax Therapeutics Inc.

Tenax Therapeutics (TENX) is implementing advanced R&D solutions for the therapy of heart pathologies and pulmonary hypertension. The debt-to-market capitalization ratio reflects the debt load dynamics, with the indicator fixed at 0.00. A team of leading cardiologists is developing life-saving medications backed by stable financial support. Anticipation of the final phase of clinical trials for the lead drug is becoming a key growth driver.

Developing drugs for heart failure therapy requires significant capital expenditures until they are procured by insurance companies. This share of debt financing in the balance sheet capitalization illustrates the dependence of Tenax Therapeutics (TENX) on borrowed funds. The metric is calculated as the ratio of total liabilities to net asset value. An increase in this metric indicates growing financial leverage, while minimal values confirm high business autonomy and stability.